Conjunctival cancer

Summary

Conjunctival cancer (MONDO:0003454) is a cancer and 3 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, sunitinib malate, and incomplete freund’s adjuvant. A subtype of ocular cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	conjunctival cancer
Mondo ID	MONDO:0003454
DOID	DOID:5467
ICD-10-CM	C69.0
ICD-11	2033444200
NCIT	C3564
SNOMED CT	363463000
UMLS	C0153628
MedGen	56316
Anatomy (UBERON)	UBERON:0001811
Is cancer (heuristic)	yes

Also known as: cancer of conjunctiva · conjunctiva cancer · conjunctival tumor · conjunctival tumour · malignant conjunctiva neoplasm · malignant conjunctiva tumor · malignant conjunctiva tumour · malignant conjunctival neoplasm · malignant conjunctival tumor · malignant conjunctival tumour · malignant neoplasm of conjunctiva · malignant neoplasm of conjunctiva (primary) · malignant neoplasm of the conjunctiva · malignant tumor of conjunctiva · malignant tumor of the conjunctiva · malignant tumour of conjunctiva · malignant tumour of the conjunctiva

Disease family

This is a subtype of ocular cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › conjunctival cancer

Related subtypes (9): lacrimal system cancer, eye carcinoma, uveal cancer, retinal cancer, cornea cancer, eye lymphoma, ocular melanoma, eyelid cancer, metastatic malignant neoplasm in the eye

Subtypes (3): malignant conjunctival melanoma, conjunctival squamous cell carcinoma, primary lymphoma of the conjunctiva

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00482911	PHASE2	TERMINATED	Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
NCT00471471	PHASE1	COMPLETED	Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT00705640	PHASE1	COMPLETED	Vaccine Therapy in Treating Patients With Advanced Melanoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	1
SUNITINIB MALATE	4	1
INCOMPLETE FREUND’S ADJUVANT	3	1
CHEMBL3109278	0	1
CHEMBL2369717	0	1